SEC Form SC 13G filed by Alkermes plc

11/14/24 1:22:34 PM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $ALKS alert in real time by email

SC 13G 1 alks13gsep24.txt UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ) ALKERMES PLC (Name of Issuer) COMMON STOCK (Title of Class of Securities) G01767105 (CUSIP NUMBER) September 30, 2024 (Date of Event which Requires Filing of Statement) Check the appropriate box to designate the Rule pursuant to which this Schedule is filed: [x] Rule 13d - 1(b) Rule 13d - 1(c) Rule 13d - 1(d) 1. Name of Reporting Person T. ROWE PRICE ASSOCIATES, INC. 52-0556948 2. Check the Appropriate Box if a Member of a Group NOT APPLICABLE 3. SEC Use Only 4. Citizenship or Place of Organization Maryland Number of Shares Beneficially Owned by Each Reporting Person With 5. Sole Voting Power* 12,925,986 6. Shared Voting Power* 0 7. Sole Dispositive Power* 12,998,606 8. Shared Dispositive Power 0 9. Aggregate Amount Beneficially Owned by Each Reporting Person 12,998,606 10. Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares NOT APPLICABLE 11. Percent of Class Represented by Amount in Row 9 7.9% 12. Type of Reporting Person IA *Any shares reported in Items 5 and 6 are also reported in Item 7. Item 1(a) Name of Issuer: ALKERMES PLC Item 1(b) Address of Issuer's Principal Executive Offices: CONNAUGHT HOUSE, 1 BURLINGTON ROAD, DUBLIN 4 L2 00000 Item 2(a) Name of Person(s) Filing: (1) T. ROWE PRICE ASSOCIATES, INC. (Price Associates) Item 2(b) Address of Principal Business Office: 100 E. Pratt Street, Baltimore, MD 21202 Item 2(c) Citizenship or Place of Organization: (1) Maryland Item 2(d) Title of Class of Securities: COMMON STOCK Item 2(e) Cusip Number: G01767105 Item 3: The person filing this Schedule 13G is an: X Investment Adviser registered under Section 203 of the Investment Advisers Act of 1940 Item 4: Reference is made to Items 5-11 on the preceding pages of this Schedule 13G. Item 5: Ownership of Five Percent or Less of a Class Not Applicable Item 6: Ownership of More than Five Percent on Behalf of Another Person (1) Price Associates does not serve as custodian of the assets of any of its clients; accordingly, in each instance only the client or the client's custodian or trustee bank has the right to receive dividends paid with respect to, and proceeds from the sale of, such securities. The ultimate power to direct the receipt of dividends paid with respect to, and the proceeds from the sale of, such securities, is vested in the individual and institutional clients which Price Associates serves as investment adviser. Any and all discretionary authority which has been delegated to Price Associates may be revoked in whole or in part at any time. Except as may be indicated if this is a joint filing with one of the registered investment companies sponsored by Price Associates which it also serves as investment adviser ("T. Rowe Price Funds"), not more than 5% of the class of such securities is owned by any one client subject to the investment advice of Price Associates. Item 7: Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. Not Applicable Item 8: Identification and Classification of Members of the Group Not Applicable Item 9: Notice of Dissolution of Group Not Applicable Item 10: Certification By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. T. Rowe Price Associates, Inc. hereby declares and affirms that the filing of Schedule 13G shall not be construed as an admission that Price Associates is the beneficial owner of the securities referred to, which beneficial ownership is expressly denied. Signature. After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. T. ROWE PRICE ASSOCIATES, INC. Date: November 14, 2024 Signature: /s/ Ellen York Name & Title: Ellen York, Vice President 09/30/2024

Get the next $ALKS alert in real time by email

Recent Analyst Ratings for

$ALKS

Date	Price Target	Rating	Analyst
9/26/2025	$44.00	Sector Perform → Outperform	RBC Capital Mkts
9/3/2025	$44.00	Overweight	Wells Fargo
7/15/2025	$43.00	Buy	Goldman
6/17/2025	$42.00	Neutral → Buy	UBS
5/28/2025	$45.00	Buy	Needham
3/13/2025	$40.00	Sector Perform	RBC Capital Mkts
3/4/2025	$21.00 → $38.00	Sell → Neutral	UBS
2/11/2025	$40.00	Buy	Deutsche Bank

More analyst ratings

SEC Form SC 13G filed by Alkermes plc

11/14/24 1:22:34 PM ET

$ALKS

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $ALKS alert in real time by email

Recent Analyst Ratings for

$ALKS

Date	Price Target	Rating	Analyst
9/26/2025	$44.00	Sector Perform → Outperform	RBC Capital Mkts
9/3/2025	$44.00	Overweight	Wells Fargo
7/15/2025	$43.00	Buy	Goldman
6/17/2025	$42.00	Neutral → Buy	UBS
5/28/2025	$45.00	Buy	Needham
3/13/2025	$40.00	Sector Perform	RBC Capital Mkts
3/4/2025	$21.00 → $38.00	Sell → Neutral	UBS
2/11/2025	$40.00	Buy	Deutsche Bank

More analyst ratings

SEC Form SC 13G filed by Alkermes plc

Crush Q3 2025 with the Best AI Superconnector

Recent Analyst Ratings for
$ALKS

SEC Form SC 13G filed by Alkermes plc

Crush Q3 2025 with the Best AI Superconnector

Recent Analyst Ratings for
$ALKS

$ALKS
Analyst Ratings

Alkermes Plc upgraded by RBC Capital Mkts with a new price target

Wells Fargo initiated coverage on Alkermes Plc with a new price target

Goldman initiated coverage on Alkermes Plc with a new price target

$ALKS
Press Releases

Alkermes Appoints Joshua Reed as Chief Financial Officer

Alkermes Announces Launch of 8th Annual Alkermes Pathways Research Awards® Program

Alkermes Presents Detailed Positive Results from Vibrance-1 Phase 2 Study of Alixorexton in Patients with Narcolepsy Type 1 at World Sleep Congress 2025

$ALKS
SEC Filings

Alkermes plc filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events

Alkermes plc filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

Alkermes plc filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

$ALKS
Insider Trading

SEC Form 3 filed by new insider Reed Joshua

EVP, CLO, Alkermes, Inc. Gaffin David Joseph converted options into 2,014 units of Ordinary Shares and covered exercise/tax liability with 895 units of Ordinary Shares, increasing direct ownership by 0.55% to 205,374 units (SEC Form 4)

SVP, Chief Commercial Officer Nichols Christian Todd sold $210,143 worth of Ordinary Shares (6,667 units at $31.52), decreasing direct ownership by 7% to 86,208 units (SEC Form 4)

$ALKS
Large Ownership Changes